

## Participant Summary

MONTH 6 OF YEAR 2021

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 15 WHOLE BLOOD GLUCOSE

ANALYTE			NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
157 WHOLE BLOOD GLUCOSE			CLIA TEST ID #: 0						EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}
2021-491	20	ABBOT FREE	22	492.227	11.297	2.30	443.000	541.000	
2021-491	23	ABBOTT PRE	25	422.600	26.295	6.22	380.000	465.000	
2021-491	27	STAT SRIP.	55	399.167	31.638	7.93	359.000	439.000	
2021-491	33	AC.CHEK II	24	569.826	7.574	1.33	513.000	627.000	
2021-491	34	FREE STYL	40	496.692	10.236	2.06	447.000	546.000	
2021-492	20	ABBOT FREE	22	143.909	7.555	5.25	130.000	158.000	
2021-492	23	ABBOTT PRE	25	131.600	6.573	4.99	118.000	145.000	
2021-492	27	STAT SRIP.	55	135.346	5.567	4.11	122.000	149.000	
2021-492	33	AC.CHEK II	24	160.087	4.138	2.58	144.000	176.000	
2021-492	34	FREE STYL	40	145.325	5.981	4.12	131.000	160.000	
2021-493	20	ABBOT FREE	22	402.318	19.137	4.76	362.000	443.000	
2021-493	23	ABBOTT PRE	25	348.458	15.229	4.37	314.000	383.000	
2021-493	27	STAT SRIP.	55	330.642	21.888	6.62	298.000	364.000	
2021-493	33	AC.CHEK II	24	444.250	12.343	2.78	400.000	489.000	
2021-493	34	FREE STYL	40	415.550	17.675	4.25	374.000	457.000	
2021-494	20	ABBOT FREE	22	279.045	13.706	4.91	251.000	307.000	
2021-494	23	ABBOTT PRE	25	246.208	11.864	4.82	222.000	271.000	
2021-494	27	STAT SRIP.	55	244.722	13.114	5.36	220.000	269.000	
2021-494	33	AC.CHEK II	24	308.125	6.307	2.05	277.000	339.000	
2021-494	34	FREE STYL	40	285.075	14.652	5.14	257.000	314.000	
2021-495	20	ABBOT FREE	22	276.727	16.349	5.91	249.000	304.000	
2021-495	23	ABBOTT PRE	25	242.875	11.770	4.85	219.000	267.000	
2021-495	27	STAT SRIP.	55	247.907	14.613	5.89	223.000	273.000	
2021-495	33	AC.CHEK II	24	307.292	6.045	1.97	277.000	338.000	
2021-495	34	FREE STYL	40	285.775	11.693	4.09	257.000	314.000	

## Participant Summary

MONTH 6 OF YEAR 2021

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 140 COAGULATION (HEMAT.)

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
080	FIBRINOGEN		CLIA TEST ID #: 825		EVALUATION CRITERIA: TARGET VALUE 20 %				
2021-551	73 ACL 8 TO E	87	HEMOSIL-C	10	191.333	15.691	8.20	153.000	230.000
2021-551	73 ACL 8 TO E	87	HEMOSIL-C	10	218.900	28.686	13.10	175.000	263.000
2021-552	73 ACL 8 TO E	87	HEMOSIL-C	10	264.100	37.703	14.28	211.000	317.000
2021-552	73 ACL 8 TO E	87	HEMOSIL-C	10	223.000	12.728	5.71	178.000	268.000
2021-553	73 ACL 8 TO E	87	HEMOSIL-C	10	236.667	20.072	8.48	189.000	284.000
2021-553	73 ACL 8 TO E	87	HEMOSIL-C	10	258.700	41.076	15.88	207.000	310.000
2021-554	73 ACL 8 TO E	87	HEMOSIL-C	10	474.200	102.044	21.52	379.000	569.000
2021-554	73 ACL 8 TO E	87	HEMOSIL-C	10	398.333	21.700	5.45	319.000	478.000
2021-555	73 ACL 8 TO E	87	HEMOSIL-C	10	145.000	5.099	3.52	116.000	174.000
2021-555	73 ACL 8 TO E	87	HEMOSIL-C	10	165.100	28.321	17.15	132.000	198.000
081	PART.THROM. TIME-PTT		CLIA TEST ID #: 835		EVALUATION CRITERIA: TARGET VALUE 15 %				
2021-551	33 MLA ELECT.	54	QUICK COAG	10	23.600	3.906	16.55	20.100	27.100
2021-551	58 AMELUNG KC	42	BIOMERIEUX	10	28.080	1.618	5.76	23.900	32.300
2021-551	58 AMELUNG KC	42	BIOMERIEUX	10	25.300	0.990	3.91	21.500	29.100
2021-551	62 DADE SYS.	35	DADE ACTIN	56	22.969	0.569	2.48	19.500	26.400
2021-551	62 DADE SYS.	35	DADE ACTIN	56	25.300	0.990	3.91	21.500	29.100
2021-551	65 DADE BFTII	35	DADE ACTIN	13	23.800	1.299	5.46	20.200	27.400
2021-551	65 DADE BFTII	35	DADE ACTIN	13	25.300	0.990	3.91	21.500	29.100
2021-551	69 DIAG.STAGO	49	STA-PTT	13	25.954	0.668	2.57	22.100	29.800
2021-551	73 ACL 8 TO E	56	PTT-HEMO	39	28.275	0.554	1.96	24.000	32.500
2021-551	73 ACL 8 TO E	56	PTT-HEMO	39	26.869	0.745	2.77	22.800	30.900
2021-551	76 STAGO STAR	49	STA-PTT	21	25.300	1.509	5.97	21.500	29.100
2021-551	79 CS-2500	35	DADE ACTIN	10	23.550	0.372	1.58	20.000	27.100

## Participant Summary

MONTH 6 OF YEAR 2021

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 140 COAGULATION (HEMAT.)

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
081	PART.THROM. TIME-PTT	CLIA TEST ID #: 835	EVALUATION CRITERIA: TARGET VALUE	15	%				
2021-552	33 MLA ELECT.	54 QUICK COAG		10	32.990	4.411	13.37	28.000	37.900
2021-552	58 AMELUNG KC	42 BIOMERIEUX		10	39.140	3.889	9.94	33.300	45.000
2021-552	58 AMELUNG KC	42 BIOMERIEUX		10	36.133	0.685	1.90	30.700	41.600
2021-552	62 DADE SYS.	35 DADE ACTIN		56	36.133	0.685	1.90	30.700	41.600
2021-552	62 DADE SYS.	35 DADE ACTIN		56	33.969	0.982	2.89	28.900	39.100
2021-552	65 DADE BFTII	35 DADE ACTIN		13	36.067	1.774	4.92	30.700	41.500
2021-552	65 DADE BFTII	35 DADE ACTIN		13	36.133	0.685	1.90	30.700	41.600
2021-552	69 DIAG.STAGO	49 STA-PTT		13	39.185	1.740	4.44	33.300	45.100
2021-552	73 ACL 8 TO E	56 PTT-HEMO		39	37.016	0.969	2.62	31.500	42.600
2021-552	73 ACL 8 TO E	56 PTT-HEMO		39	38.175	0.593	1.55	32.400	43.900
2021-552	76 STAGO STAR	49 STA-PTT		21	38.157	3.211	8.42	32.400	43.900
2021-552	79 CS-2500	35 DADE ACTIN		10	35.450	0.878	2.48	30.100	40.800
2021-553	33 MLA ELECT.	54 QUICK COAG		10	38.770	4.687	12.09	33.000	44.600
2021-553	58 AMELUNG KC	42 BIOMERIEUX		10	45.170	4.901	10.85	38.400	51.900
2021-553	58 AMELUNG KC	42 BIOMERIEUX		10	43.433	1.554	3.58	36.900	49.900
2021-553	62 DADE SYS.	35 DADE ACTIN		56	39.625	1.429	3.61	33.700	45.600
2021-553	62 DADE SYS.	35 DADE ACTIN		56	43.433	1.554	3.58	36.900	49.900
2021-553	65 DADE BFTII	35 DADE ACTIN		13	44.342	1.801	4.06	37.700	51.000
2021-553	65 DADE BFTII	35 DADE ACTIN		13	43.433	1.554	3.58	36.900	49.900
2021-553	69 DIAG.STAGO	49 STA-PTT		13	47.392	2.297	4.85	40.300	54.500
2021-553	73 ACL 8 TO E	56 PTT-HEMO		39	45.550	0.953	2.09	38.700	52.400
2021-553	73 ACL 8 TO E	56 PTT-HEMO		39	44.495	1.584	3.56	37.800	51.200
2021-553	76 STAGO STAR	49 STA-PTT		21	46.090	4.167	9.04	39.200	53.000
2021-553	79 CS-2500	35 DADE ACTIN		10	42.150	1.569	3.72	35.800	48.500
2021-554	33 MLA ELECT.	54 QUICK COAG		10	30.170	5.863	19.43	25.600	34.700
2021-554	58 AMELUNG KC	42 BIOMERIEUX		10	29.210	1.977	6.77	24.800	33.600
2021-554	58 AMELUNG KC	42 BIOMERIEUX		10	27.000	0.283	1.05	23.000	31.100

## Participant Summary

### MONTH 6 OF YEAR 2021

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 140 COAGULATION (HEMAT.)

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2021-554	62 DADE SYS.	35 DADE	ACTIN	56	27.000	0.283	1.05	23.000	31.100
2021-554	62 DADE SYS.	35 DADE	ACTIN	56	24.000	0.655	2.73	20.400	27.600
2021-554	65 DADE BFTII	35 DADE	ACTIN	13	23.642	2.184	9.24	20.100	27.200
2021-554	65 DADE BFTII	35 DADE	ACTIN	13	27.000	0.283	1.05	23.000	31.100
2021-554	69 DIAG.STAGO	49 STA-	PTT	13	29.954	1.494	4.99	25.500	34.400
2021-554	73 ACL 8 TO E	56 PTT-	HEMO	39	38.645	2.039	5.28	32.800	44.400
2021-554	73 ACL 8 TO E	56 PTT-	HEMO	39	39.975	0.676	1.69	34.000	46.000
2021-554	76 STAGO STAR	49 STA-	PTT	21	29.714	3.134	10.55	25.300	34.200
2021-554	79 CS-2500	35 DADE	ACTIN	10	24.400	0.293	1.20	20.700	28.100
081	PART.THROM. TIME-PTT	CLIA TEST ID #: 835	EVALUATION CRITERIA: TARGET VALUE 15 %						
2021-555	33 MLA ELECT.	54 QUICK	COAG	10	24.000	3.609	15.04	20.400	27.600
2021-555	58 AMELUNG KC	42 BIOMERIEUX		10	31.820	2.905	9.13	27.000	36.600
2021-555	58 AMELUNG KC	42 BIOMERIEUX		10	27.433	1.934	7.05	23.300	31.500
2021-555	62 DADE SYS.	35 DADE	ACTIN	56	23.932	0.620	2.59	20.300	27.500
2021-555	62 DADE SYS.	35 DADE	ACTIN	56	27.433	1.934	7.05	23.300	31.500
2021-555	65 DADE BFTII	35 DADE	ACTIN	13	25.408	1.925	7.58	21.600	29.200
2021-555	65 DADE BFTII	35 DADE	ACTIN	13	27.433	1.934	7.05	23.300	31.500
2021-555	69 DIAG.STAGO	49 STA-	PTT	13	29.315	1.357	4.63	24.900	33.700
2021-555	73 ACL 8 TO E	56 PTT-	HEMO	39	28.250	0.391	1.38	24.000	32.500
2021-555	73 ACL 8 TO E	56 PTT-	HEMO	39	28.784	0.662	2.30	24.500	33.100
2021-555	76 STAGO STAR	49 STA-	PTT	21	29.362	2.561	8.72	25.000	33.800
2021-555	79 CS-2500	35 DADE	ACTIN	10	25.010	0.556	2.22	21.300	28.800
082	PROTHROMBIN TIME(P.T)	CLIA TEST ID #: 845							
2021-551	33 MLA ELECT.	37 QUICK	COAG	10	13.740	3.660	26.64	11.700	15.800
2021-551	33 MLA ELECT.	37 QUICK	COAG	10	12.833	0.189	1.47	10.900	14.800
2021-551	58 AMELUNG KC	15 BIOMERIEUX		12	11.392	0.492	4.32	9.700	13.100
2021-551	62 DADE SYS.	33 DADE	INNOV	57	11.022	0.239	2.17	9.400	12.700
2021-551	62 DADE SYS.	33 DADE	INNOV	57	10.696	0.285	2.66	9.100	12.300
2021-551	65 DADE BFTII	33 DADE	INNOV	15	10.350	0.508	4.91	8.800	11.900
2021-551	73 ACL 8 TO E	41 HEMOSIL RE		34	11.300	0.122	1.08	9.600	13.000

## Participant Summary

MONTH 6 OF YEAR 2021

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 140 COAGULATION (HEMAT.)

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2021-551	73	ACL 8 TO E	41 HEMOSIL RE	34	11.318	0.242	2.14	9.600	13.000
2021-551	76	STAGO STAR	44 STA NEO CI	16	12.931	0.310	2.39	11.000	14.900
2021-551	76	STAGO STAR	44 STA NEO CI	16	13.360	0.742	5.55	11.400	15.400
2021-551	79	CS-2500	33 DADE INNOV	10	11.210	0.247	2.20	9.500	12.900
082 PROTHROMBIN TIME(PT)		CLIA TEST ID #: 845		EVALUATION CRITERIA: TARGET VALUE 15 %					
2021-552	33	MLA ELECT.	37 QUICK COAG	10	20.180	4.728	23.43	17.200	23.200
2021-552	33	MLA ELECT.	37 QUICK COAG	10	25.700	1.023	3.98	21.800	29.600
2021-552	58	AMELUNG KC	15 BIOMERIEUX	12	15.433	1.470	9.52	13.100	17.700
2021-552	62	DADE SYS.	33 DADE INNOV	57	19.232	0.819	4.26	16.300	22.100
2021-552	62	DADE SYS.	33 DADE INNOV	57	19.433	0.593	3.05	16.500	22.300
2021-552	65	DADE BFTII	33 DADE INNOV	15	21.093	1.296	6.14	17.900	24.300
2021-552	73	ACL 8 TO E	41 HEMOSIL RE	34	24.125	0.760	3.15	20.500	27.700
2021-552	73	ACL 8 TO E	41 HEMOSIL RE	34	23.988	1.201	5.01	20.400	27.600
2021-552	76	STAGO STAR	44 STA NEO CI	16	25.480	0.662	2.60	21.700	29.300
2021-552	76	STAGO STAR	44 STA NEO CI	16	26.050	1.591	6.11	22.100	30.000
2021-552	79	CS-2500	33 DADE INNOV	10	19.800	0.349	1.76	16.800	22.800
2021-553	33	MLA ELECT.	37 QUICK COAG	10	26.610	4.710	17.70	22.600	30.600
2021-553	33	MLA ELECT.	37 QUICK COAG	10	36.133	2.288	6.33	30.700	41.600
2021-553	58	AMELUNG KC	15 BIOMERIEUX	12	18.883	2.406	12.74	16.100	21.700
2021-553	62	DADE SYS.	33 DADE INNOV	57	26.344	0.885	3.36	22.400	30.300
2021-553	62	DADE SYS.	33 DADE INNOV	57	26.270	1.110	4.23	22.300	30.200
2021-553	65	DADE BFTII	33 DADE INNOV	15	30.343	1.850	6.10	25.800	34.900
2021-553	73	ACL 8 TO E	41 HEMOSIL RE	34	34.858	1.803	5.17	29.600	40.100
2021-553	73	ACL 8 TO E	41 HEMOSIL RE	34	36.100	1.192	3.30	30.700	41.500
2021-553	76	STAGO STAR	44 STA NEO CI	16	36.419	2.674	7.34	31.000	41.900
2021-553	76	STAGO STAR	44 STA NEO CI	16	35.960	1.938	5.39	30.600	41.400
2021-553	79	CS-2500	33 DADE INNOV	10	26.770	0.329	1.23	22.800	30.800
2021-554	33	MLA ELECT.	37 QUICK COAG	10	14.770	5.081	34.40	12.600	17.000

## Participant Summary

MONTH 6 OF YEAR 2021

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 140 COAGULATION (HEMAT.)

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2021-554	33	MLA ELECT.	37 QUICK COAG	10	13.933	0.694	4.98	11.800	16.000
2021-554	58	AMELUNG KC	15 BIOMERIEUX	12	11.600	0.992	8.55	9.900	13.300
2021-554	62	DADE SYS.	33 DADE INNOV	57	10.952	0.415	3.79	9.300	12.600
2021-554	62	DADE SYS.	33 DADE INNOV	57	11.133	0.216	1.94	9.500	12.800
2021-554	65	DADE BFTII	33 DADE INNOV	15	10.600	0.568	5.36	9.000	12.200
2021-554	73	ACL 8 TO E	41 HEMOSIL RE	34	11.700	0.141	1.21	9.900	13.500
2021-554	73	ACL 8 TO E	41 HEMOSIL RE	34	11.797	0.244	2.07	10.000	13.600
2021-554	76	STAGO STAR	44 STA NEO CI	16	14.080	1.292	9.18	12.000	16.200
2021-554	76	STAGO STAR	44 STA NEO CI	16	13.856	0.298	2.15	11.800	15.900
2021-554	79	CS-2500	33 DADE INNOV	10	11.300	0.141	1.25	9.600	13.000
082 PROTHROMBIN TIME(PT)		CLIA TEST ID #: 845		EVALUATION CRITERIA: TARGET VALUE 15 %					
2021-555	33	MLA ELECT.	37 QUICK COAG	10	14.360	3.449	24.01	12.200	16.500
2021-555	33	MLA ELECT.	37 QUICK COAG	10	14.433	0.834	5.78	12.300	16.600
2021-555	58	AMELUNG KC	15 BIOMERIEUX	12	12.258	0.924	7.54	10.400	14.100
2021-555	62	DADE SYS.	33 DADE INNOV	57	12.122	0.215	1.77	10.300	13.900
2021-555	62	DADE SYS.	33 DADE INNOV	57	11.830	0.333	2.82	10.100	13.600
2021-555	65	DADE BFTII	33 DADE INNOV	15	11.829	0.636	5.38	10.100	13.600
2021-555	73	ACL 8 TO E	41 HEMOSIL RE	34	12.838	0.338	2.63	10.900	14.800
2021-555	73	ACL 8 TO E	41 HEMOSIL RE	34	12.600	0.187	1.48	10.700	14.500
2021-555	76	STAGO STAR	44 STA NEO CI	16	13.900	0.389	2.80	11.800	16.000
2021-555	76	STAGO STAR	44 STA NEO CI	16	14.280	0.798	5.59	12.100	16.400
2021-555	79	CS-2500	33 DADE INNOV	10	12.270	0.228	1.86	10.400	14.100

## Participant Summary

### MONTH 6 OF YEAR 2021

SPE: 20 HEMATOLOGY		SUB: 70 GENERAL			GRP: 100 HEMA. CELL IDENTIFI.						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
072 HEMA. CELL IDENTIFI.											
2021-501					008	008	006 - SEGMENTED	857	1	853	0
2021-501					008	008	007 - BASOPHIL,	857	3	853	0
2021-501					008	008	008 - EOSINOPHIL	857	853	853	100
2021-502					030	030	013 - LYMPHOCYTE	857	1	677	0
2021-502					030	030	030 - ERYTHROCYT	857	677	677	100
2021-502					030	030	033 - POLYCHROMA	857	1	677	0
2021-502					030	030	044 - ERYTHROCYT	857	28	677	0
2021-502					030	030	046 - ERYTHROCYT	857	1	677	0
2021-502					030	030	048 - ERYTHROCYT	857	149	677	0
2021-503					005	005	017 - MONOCYTE	857	3	853	0
2021-503					005	005	020 - GIANT PLA	857	1	853	0
2021-503					005	005	005 - BAND (STAB	857	853	853	100
2021-504					014	014	014 - LYMPHOCYTE	857	836	836	100
2021-504					014	014	016 - PLASMACYTE	857	1	836	0
2021-504					014	014	017 - MONOCYTE	857	20	836	0
2021-505					001	001	001 - BLAST	857	853	853	100
2021-505					001	001	002 - PROMYELOCY	857	2	853	0
2021-505					001	001	003 - MYELOCYTE	857	2	853	0

## Participant Summary

MONTH 6 OF YEAR 2021

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 137 RETICULOCYTE COUNT

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
149	RETICULOCYTE COUNT	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD OR 25 %	{GREATER}			
2021-531	7	M.B.MANUAL		18	1.489	0.505	33.94	0.000	3.000
2021-531	9	M.B. RICCA		29	1.476	0.354	23.98	0.400	2.500
2021-531	24	Unicel DxH		13	0.746	0.093	12.46	0.500	1.000
2021-531	25	SYSMEX XN		24	1.013	0.097	9.59	0.700	1.300
2021-532	7	M.B.MANUAL		18	6.161	1.789	29.04	0.800	11.500
2021-532	9	M.B. RICCA		29	5.503	1.385	25.17	1.300	9.700
2021-532	24	Unicel DxH		13	3.415	0.400	11.70	2.200	4.600
2021-532	25	SYSMEX XN		24	2.592	0.297	11.46	1.700	3.500
2021-533	7	M.B.MANUAL		18	12.528	4.372	34.90	0	25.600
2021-533	9	M.B. RICCA		29	10.752	1.792	16.67	5.400	16.100
2021-533	24	Unicel DxH		13	7.931	0.500	6.30	5.900	9.900
2021-533	25	SYSMEX XN		24	5.058	0.594	11.75	3.300	6.800
2021-534	7	M.B.MANUAL		18	12.333	4.693	38.05	0	26.400
2021-534	9	M.B. RICCA		29	11.066	1.983	17.92	5.100	17.000
2021-534	24	Unicel DxH		13	8.008	0.512	6.40	6.000	10.000
2021-534	25	SYSMEX XN		24	5.017	0.754	15.02	2.800	7.300
2021-535	7	M.B.MANUAL		18	1.341	0.377	28.14	0.200	2.500
2021-535	9	M.B. RICCA		29	1.407	0.384	27.32	0.300	2.600
2021-535	24	Unicel DxH		13	0.746	0.093	12.46	0.500	1.000
2021-535	25	SYSMEX XN		24	0.992	0.081	8.19	0.700	1.200

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW



**Participant Summary**

**MONTH 6 OF YEAR 2021**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
172 DIFF. WBC FOR 5 PAR.		CLIA TEST ID #: 765	EVALUATION CRITERIA: TARGET VALUE	25 % OR 2.00	{GREATER}						
2021521x	2 ACT PENTRA	1 NEUTROPHIL	15 COUL ACT 5		140	71.961	1.536	2.13	54.000	90.000	
2021521x	2 ACT PENTRA	1 NEUTROPHIL	24 ABX PENTRA		25	69.112	1.656	2.40	51.800	86.400	
2021521x	2 ACT PENTRA	2 LYMPHOCYTE	15 COUL ACT 5		140	18.839	1.237	6.56	14.100	23.500	
2021521x	2 ACT PENTRA	2 LYMPHOCYTE	24 ABX PENTRA		25	16.840	1.348	8.01	12.600	21.100	
2021521x	2 ACT PENTRA	3 MONOCYTE	15 COUL ACT 5		141	4.469	0.864	19.32	2.500	6.500	
2021521x	2 ACT PENTRA	3 MONOCYTE	24 ABX PENTRA		25	5.040	0.826	16.39	3.000	7.000	
2021521x	2 ACT PENTRA	4 EOSINOPHIL	15 COUL ACT 5		139	4.712	0.301	6.39	2.700	6.700	
2021521x	2 ACT PENTRA	4 EOSINOPHIL	24 ABX PENTRA		25	4.784	0.323	6.76	2.800	6.800	
2021521x	2 ACT PENTRA	5 BASOPHIL	15 COUL ACT 5		140	85.401	1.566	1.83	64.100	106.800	
2021521x	2 ACT PENTRA	5 BASOPHIL	24 ABX PENTRA		25	4.216	0.112	2.66	2.200	6.200	
2021521x	3 ADVIA 120	1 NEUTROPHIL	9 ADVIA-120		16	70.744	0.570	0.81	53.100	88.400	
2021521x	3 ADVIA 120	2 LYMPHOCYTE	9 ADVIA-120		16	14.550	0.664	4.57	10.900	18.200	
2021521x	3 ADVIA 120	3 MONOCYTE	9 ADVIA-120		16	7.763	0.154	1.98	5.800	9.800	
2021521x	3 ADVIA 120	4 EOSINOPHIL	9 ADVIA-120		16	4.400	0.494	11.22	2.400	6.400	
2021521x	3 ADVIA 120	5 BASOPHIL	9 ADVIA-120		16	0.281	0.101	36.04	0	2.300	
2021521x	3 ADVIA 120	6 LUC	9 ADVIA-120		16	2.463	0.276	11.20	0.500	4.500	
2021521x	7 DXH	1 NEUTROPHIL	36 BC DXH 500		26	82.896	2.533	3.06	62.200	103.600	
2021521x	7 DXH	2 LYMPHOCYTE	36 BC DXH 500		26	7.700	2.212	28.73	5.700	9.700	
2021521x	7 DXH	3 MONOCYTE	36 BC DXH 500		25	0.200	0.187	93.54	0	2.200	
2021521x	7 DXH	4 EOSINOPHIL	36 BC DXH 500		26	9.342	0.577	6.18	7.000	11.700	
2021521x	7 DXH	5 BASOPHIL	36 BC DXH 500		25	0.021	0.041	194.94	0	2.000	
2021522x	2 ACT PENTRA	1 NEUTROPHIL	15 COUL ACT 5		140	57.231	2.115	3.70	42.900	71.500	
2021522x	2 ACT PENTRA	1 NEUTROPHIL	24 ABX PENTRA		25	56.228	2.154	3.83	42.200	70.300	
2021522x	2 ACT PENTRA	2 LYMPHOCYTE	15 COUL ACT 5		140	33.300	1.953	5.86	25.000	41.600	
2021522x	2 ACT PENTRA	2 LYMPHOCYTE	24 ABX PENTRA		25	30.648	2.024	6.60	23.000	38.300	
2021522x	2 ACT PENTRA	3 MONOCYTE	15 COUL ACT 5		140	4.711	0.852	18.08	2.700	6.700	
2021522x	2 ACT PENTRA	3 MONOCYTE	24 ABX PENTRA		25	5.100	0.773	15.15	3.100	7.100	
2021522x	2 ACT PENTRA	4 EOSINOPHIL	15 COUL ACT 5		140	4.732	0.486	10.27	2.700	6.700	

**Participant Summary**

**MONTH 6 OF YEAR 2021**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2021522x	2	ACT PENTRA	4 EOSINOPHIL	24	ABX PENTRA	25	4.736	0.449	9.48	2.700	6.700
2021522x	2	ACT PENTRA	5 BASOPHIL	15	COUL ACT 5	140	66.972	1.924	2.87	50.200	83.700
2021522x	2	ACT PENTRA	5 BASOPHIL	24	ABX PENTRA	25	3.308	0.070	2.12	1.300	5.300
2021522x	3	ADVIA 120	1 NEUTROPHIL	9	ADVIA-120	16	62.563	0.919	1.47	46.900	78.200
2021522x	3	ADVIA 120	2 LYMPHOCYTE	9	ADVIA-120	16	24.206	0.869	3.59	18.200	30.300
2021522x	3	ADVIA 120	3 MONOCYTE	9	ADVIA-120	16	6.969	0.487	6.99	5.000	9.000
2021522x	3	ADVIA 120	4 EOSINOPHIL	9	ADVIA-120	16	2.450	0.400	16.33	0.500	4.500
2021522x	3	ADVIA 120	5 BASOPHIL	9	ADVIA-120	16	0.450	0.158	35.14	0	2.500
2021522x	3	ADVIA 120	6 LUC	9	ADVIA-120	16	3.700	0.359	9.70	1.700	5.700
2021522x	7	DXH	1 NEUTROPHIL	36	BC DXH 500	26	55.831	5.442	9.75	41.900	69.800
2021522x	7	DXH	2 LYMPHOCYTE	36	BC DXH 500	26	31.664	5.135	16.22	23.700	39.600
2021522x	7	DXH	3 MONOCYTE	36	BC DXH 500	26	0.038	0.048	129.10	0	2.000
2021522x	7	DXH	4 EOSINOPHIL	36	BC DXH 500	26	12.620	0.971	7.70	9.500	15.800
2021522x	7	DXH	5 BASOPHIL	36	BC DXH 500	25	0.021	0.041	194.94	0	2.000
172 DIFF. WBC FOR 5 PAR.			CLIA TEST ID #: 765			EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}					
2021523x	2	ACT PENTRA	1 NEUTROPHIL	15	COUL ACT 5	140	52.935	3.970	7.50	39.700	66.200
2021523x	2	ACT PENTRA	1 NEUTROPHIL	24	ABX PENTRA	25	50.320	3.019	6.00	37.700	62.900
2021523x	2	ACT PENTRA	2 LYMPHOCYTE	15	COUL ACT 5	140	32.860	2.353	7.16	24.600	41.100
2021523x	2	ACT PENTRA	2 LYMPHOCYTE	24	ABX PENTRA	25	30.288	3.074	10.15	22.700	37.900
2021523x	2	ACT PENTRA	3 MONOCYTE	15	COUL ACT 5	140	7.450	2.052	27.55	5.500	9.500
2021523x	2	ACT PENTRA	3 MONOCYTE	24	ABX PENTRA	25	9.292	1.314	14.14	7.000	11.600
2021523x	2	ACT PENTRA	4 EOSINOPHIL	15	COUL ACT 5	139	6.582	0.617	9.37	4.600	8.600
2021523x	2	ACT PENTRA	4 EOSINOPHIL	24	ABX PENTRA	25	7.248	1.478	20.39	5.200	9.200
2021523x	2	ACT PENTRA	5 BASOPHIL	15	COUL ACT 5	141	61.254	1.713	2.80	45.900	76.600
2021523x	2	ACT PENTRA	5 BASOPHIL	24	ABX PENTRA	25	3.046	0.064	2.11	1.000	5.000
2021523x	3	ADVIA 120	1 NEUTROPHIL	9	ADVIA-120	16	44.644	1.951	4.37	33.500	55.800
2021523x	3	ADVIA 120	2 LYMPHOCYTE	9	ADVIA-120	16	33.813	1.325	3.92	25.400	42.300
2021523x	3	ADVIA 120	3 MONOCYTE	9	ADVIA-120	16	13.956	0.821	5.88	10.500	17.400
2021523x	3	ADVIA 120	4 EOSINOPHIL	9	ADVIA-120	16	1.594	0.293	18.36	0	3.600
2021523x	3	ADVIA 120	5 BASOPHIL	9	ADVIA-120	16	0.550	0.330	59.96	0	2.600
2021523x	3	ADVIA 120	6 LUC	9	ADVIA-120	16	5.213	0.957	18.36	3.200	7.200

**Participant Summary**

**MONTH 6 OF YEAR 2021**

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE							NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2021523x	7 DXH	1 NEUTROPHIL	36 BC DXH 500	26	82.908	2.261	2.73	62.200	103.600			
2021523x	7 DXH	2 LYMPHOCYTE	36 BC DXH 500	26	7.448	2.080	27.93	5.400	9.400			
2021523x	7 DXH	3 MONOCYTE	36 BC DXH 500	25	0.204	0.184	89.96	0	2.200			
2021523x	7 DXH	4 EOSINOPHIL	36 BC DXH 500	26	9.342	0.609	6.52	7.000	11.700			
2021523x	7 DXH	5 BASOPHIL	36 BC DXH 500	25	0.042	0.122	293.26	0	2.000			
172 DIFF. WBC FOR 5 PAR.		CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}								
2021524x	2 ACT PENTRA	1 NEUTROPHIL	15 COUL ACT 5	139	72.091	1.543	2.14	54.100	90.100			
2021524x	2 ACT PENTRA	1 NEUTROPHIL	24 ABX PENTRA	25	68.936	1.558	2.26	51.700	86.200			
2021524x	2 ACT PENTRA	2 LYMPHOCYTE	15 COUL ACT 5	140	18.609	1.294	6.96	14.000	23.300			
2021524x	2 ACT PENTRA	2 LYMPHOCYTE	24 ABX PENTRA	25	16.908	1.472	8.71	12.700	21.100			
2021524x	2 ACT PENTRA	3 MONOCYTE	15 COUL ACT 5	139	4.539	0.890	19.60	2.500	6.500			
2021524x	2 ACT PENTRA	3 MONOCYTE	24 ABX PENTRA	25	5.108	0.899	17.61	3.100	7.100			
2021524x	2 ACT PENTRA	4 EOSINOPHIL	15 COUL ACT 5	141	4.705	0.354	7.53	2.700	6.700			
2021524x	2 ACT PENTRA	4 EOSINOPHIL	24 ABX PENTRA	25	4.848	0.402	8.29	2.800	6.800			
2021524x	2 ACT PENTRA	5 BASOPHIL	15 COUL ACT 5	140	85.164	1.508	1.77	63.900	106.500			
2021524x	2 ACT PENTRA	5 BASOPHIL	24 ABX PENTRA	25	4.216	0.097	2.29	2.200	6.200			
2021524x	3 ADVIA 120	1 NEUTROPHIL	9 ADVIA-120	16	71.138	0.648	0.91	53.400	88.900			
2021524x	3 ADVIA 120	2 LYMPHOCYTE	9 ADVIA-120	16	14.388	0.552	3.84	10.800	18.000			
2021524x	3 ADVIA 120	3 MONOCYTE	9 ADVIA-120	16	7.700	0.262	3.41	5.700	9.700			
2021524x	3 ADVIA 120	4 EOSINOPHIL	9 ADVIA-120	16	4.288	0.485	11.30	2.300	6.300			
2021524x	3 ADVIA 120	5 BASOPHIL	9 ADVIA-120	16	0.319	0.101	31.80	0	2.300			
2021524x	3 ADVIA 120	6 LUC	9 ADVIA-120	16	2.444	0.300	12.27	0.400	4.400			
2021524x	7 DXH	1 NEUTROPHIL	36 BC DXH 500	26	68.772	0.984	1.43	51.600	86.000			
2021524x	7 DXH	2 LYMPHOCYTE	36 BC DXH 500	26	26.608	1.367	5.14	20.000	33.300			
2021524x	7 DXH	3 MONOCYTE	36 BC DXH 500	25	0.240	0.264	109.92	0	2.200			
2021524x	7 DXH	4 EOSINOPHIL	36 BC DXH 500	26	3.985	0.640	16.05	2.000	6.000			
2021524x	7 DXH	5 BASOPHIL	36 BC DXH 500	25	0.440	0.561	127.60	0	2.400			
2021525x	2 ACT PENTRA	1 NEUTROPHIL	15 COUL ACT 5	139	53.241	3.691	6.93	39.900	66.600			
2021525x	2 ACT PENTRA	1 NEUTROPHIL	24 ABX PENTRA	25	51.236	3.044	5.94	38.400	64.000			

**Participant Summary**

**MONTH 6 OF YEAR 2021**

SPEC: 20 HEMATOLOGY      SUB: 70 GENERAL      GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2021525x	2	ACT PENTRA	2 LYMPHOCYTE	15	COUL ACT 5	140	32.515	2.435	7.49	24.400	40.600
2021525x	2	ACT PENTRA	2 LYMPHOCYTE	24	ABX PENTRA	25	29.376	2.454	8.35	22.000	36.700
2021525x	2	ACT PENTRA	3 MONOCYTE	15	COUL ACT 5	140	7.487	2.026	27.06	5.500	9.500
2021525x	2	ACT PENTRA	3 MONOCYTE	24	ABX PENTRA	25	9.092	1.514	16.65	6.800	11.400
2021525x	2	ACT PENTRA	4 EOSINOPHIL	15	COUL ACT 5	140	6.655	0.755	11.34	4.700	8.700
2021525x	2	ACT PENTRA	4 EOSINOPHIL	24	ABX PENTRA	25	6.904	1.270	18.39	4.900	8.900
2021525x	2	ACT PENTRA	5 BASOPHIL	15	COUL ACT 5	141	61.303	1.630	2.66	46.000	76.600
2021525x	2	ACT PENTRA	5 BASOPHIL	24	ABX PENTRA	25	3.058	0.057	1.87	1.100	5.100
2021525x	3	ADVIA 120	1 NEUTROPHIL	9	ADVIA-120	16	44.819	1.120	2.50	33.600	56.000
2021525x	3	ADVIA 120	2 LYMPHOCYTE	9	ADVIA-120	16	33.569	1.160	3.45	25.200	42.000
2021525x	3	ADVIA 120	3 MONOCYTE	9	ADVIA-120	16	14.581	0.706	4.84	10.900	18.200
2021525x	3	ADVIA 120	4 EOSINOPHIL	9	ADVIA-120	16	1.606	0.446	27.80	0	3.600
2021525x	3	ADVIA 120	5 BASOPHIL	9	ADVIA-120	16	0.600	0.232	38.64	0	2.600
2021525x	3	ADVIA 120	6 LUC	9	ADVIA-120	16	5.081	0.855	16.83	3.100	7.100
2021525x	7	DXH	1 NEUTROPHIL	36	BC DXH 500	26	54.915	5.399	9.83	41.200	68.600
2021525x	7	DXH	2 LYMPHOCYTE	36	BC DXH 500	26	32.208	4.622	14.35	24.200	40.300
2021525x	7	DXH	3 MONOCYTE	36	BC DXH 500	25	0.057	0.058	102.05	0	2.100
2021525x	7	DXH	4 EOSINOPHIL	36	BC DXH 500	26	13.165	1.287	9.77	9.900	16.500
2021525x	7	DXH	5 BASOPHIL	36	BC DXH 500	25	0.017	0.038	217.94	0	2.000

SPEC: 20 HEMATOLOGY      SUB: 70 GENERAL      GRP: 128 DIFF 3 PARAMETER INS

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
186 DIFF 3 PARAMETER INS						CLIA TEST ID #: 765      EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}					
2021521z	8	3ST	1 Lymphocyte	1	KX 21 - Sy	41	60.618	0.541	0.89	45.500	75.800

## Participant Summary

MONTH 6 OF YEAR 2021

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 128 DIFF 3 PARAMETER INS

ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2021521z	8 3ST	1	Lymphocyte	3	ABBOTT C-D	45	59.386	1.304	2.20	44.500	74.200		
2021521z	8 3ST	2	Mix M/E/Ba	1	KX 21 - Sy	41	13.520	0.626	4.63	10.100	16.900		
2021521z	8 3ST	2	Mix M/E/Ba	3	ABBOTT C-D	45	10.668	0.666	6.25	8.000	13.300		
2021521z	8 3ST	3	Neutrophil	1	KX 21 - Sy	41	25.790	0.763	2.96	19.300	32.200		
2021521z	8 3ST	3	Neutrophil	3	ABBOTT C-D	45	30.043	1.360	4.53	22.500	37.600		
2021521z	9 3D	1	Lymphocyte	2	AcT Diff 2	22	14.065	0.453	3.22	10.500	17.600		
2021521z	9 3D	1	Lymphocyte	4	JT - Coult	14	14.071	1.040	7.39	10.600	17.600		
2021521z	9 3D	2	Mix M/E/Ba	2	AcT Diff 2	22	4.075	0.571	14.01	2.100	6.100		
2021521z	9 3D	2	Mix M/E/Ba	4	JT - Coult	15	3.586	0.595	16.59	1.600	5.600		
2021521z	9 3D	3	Neutrophil	2	AcT Diff 2	22	81.860	0.800	0.98	61.400	102.300		
2021521z	9 3D	3	Neutrophil	4	JT - Coult	14	82.143	0.959	1.17	61.600	102.700		
186 DIFF 3 PARAMETER INS		CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}									
2021522z	8 3ST	1	Lymphocyte	1	KX 21 - Sy	41	29.720	0.848	2.85	22.300	37.100		
2021522z	8 3ST	1	Lymphocyte	3	ABBOTT C-D	45	30.457	1.478	4.85	22.800	38.100		
2021522z	8 3ST	2	Mix M/E/Ba	1	KX 21 - Sy	41	17.160	0.929	5.42	12.900	21.500		
2021522z	8 3ST	2	Mix M/E/Ba	3	ABBOTT C-D	46	12.180	1.371	11.26	9.100	15.200		
2021522z	8 3ST	3	Neutrophil	1	KX 21 - Sy	41	53.041	1.228	2.32	39.800	66.300		
2021522z	8 3ST	3	Neutrophil	3	ABBOTT C-D	44	57.635	1.968	3.41	43.200	72.000		
2021522z	9 3D	1	Lymphocyte	2	AcT Diff 2	22	32.740	0.816	2.49	24.600	40.900		
2021522z	9 3D	1	Lymphocyte	4	JT - Coult	15	32.943	2.019	6.13	24.700	41.200		
2021522z	9 3D	2	Mix M/E/Ba	2	AcT Diff 2	22	6.245	0.696	11.15	4.200	8.200		
2021522z	9 3D	2	Mix M/E/Ba	4	JT - Coult	14	5.414	0.853	15.76	3.400	7.400		
2021522z	9 3D	3	Neutrophil	2	AcT Diff 2	22	60.833	1.411	2.32	45.600	76.000		
2021522z	9 3D	3	Neutrophil	4	JT - Coult	14	61.215	1.250	2.04	45.900	76.500		
2021523z	8 3ST	1	Lymphocyte	1	KX 21 - Sy	41	11.737	1.119	9.54	8.800	14.700		
2021523z	8 3ST	1	Lymphocyte	3	ABBOTT C-D	44	13.432	1.744	12.98	10.100	16.800		
2021523z	8 3ST	2	Mix M/E/Ba	1	KX 21 - Sy	41	19.010	1.386	7.29	14.300	23.800		
2021523z	8 3ST	2	Mix M/E/Ba	3	ABBOTT C-D	47	13.417	2.391	17.82	10.100	16.800		
2021523z	8 3ST	3	Neutrophil	1	KX 21 - Sy	41	69.254	1.572	2.27	51.900	86.600		

## Participant Summary

MONTH 6 OF YEAR 2021

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 128 DIFF 3 PARAMETER INS

ANALYTE								NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH				
2021523z	8 3ST	3 Neutrophil	3 ABBOTT C-D	44	73.398	2.603	3.55	55.000	91.700				
2021523z	9 3D	1 Lymphocyte	2 AcT Diff 2	22	63.620	1.794	2.82	47.700	79.500				
2021523z	9 3D	1 Lymphocyte	4 JT - Coult	15	64.529	1.365	2.11	48.400	80.700				
2021523z	9 3D	2 Mix M/E/Ba	2 AcT Diff 2	22	5.195	1.449	27.90	3.200	7.200				
2021523z	9 3D	2 Mix M/E/Ba	4 JT - Coult	14	4.214	1.139	27.04	2.200	6.200				
2021523z	9 3D	3 Neutrophil	2 AcT Diff 2	22	31.195	2.388	7.65	23.400	39.000				
2021523z	9 3D	3 Neutrophil	4 JT - Coult	14	31.257	1.575	5.04	23.400	39.100				
186 DIFF 3 PARAMETER INS		CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}									
2021524z	8 3ST	1 Lymphocyte	1 KX 21 - Sy	41	60.610	0.719	1.19	45.500	75.800				
2021524z	8 3ST	1 Lymphocyte	3 ABBOTT C-D	44	59.377	1.431	2.41	44.500	74.200				
2021524z	8 3ST	2 Mix M/E/Ba	1 KX 21 - Sy	42	13.763	0.657	4.77	10.300	17.200				
2021524z	8 3ST	2 Mix M/E/Ba	3 ABBOTT C-D	45	10.573	0.805	7.62	7.900	13.200				
2021524z	8 3ST	3 Neutrophil	1 KX 21 - Sy	40	25.618	0.661	2.58	19.200	32.000				
2021524z	8 3ST	3 Neutrophil	3 ABBOTT C-D	45	29.993	1.581	5.27	22.500	37.500				
2021524z	9 3D	1 Lymphocyte	2 AcT Diff 2	22	14.125	0.575	4.07	10.600	17.700				
2021524z	9 3D	1 Lymphocyte	4 JT - Coult	15	13.967	1.002	7.18	10.500	17.500				
2021524z	9 3D	2 Mix M/E/Ba	2 AcT Diff 2	23	4.395	1.435	32.66	2.400	6.400				
2021524z	9 3D	2 Mix M/E/Ba	4 JT - Coult	14	3.614	0.407	11.26	1.600	5.600				
2021524z	9 3D	3 Neutrophil	2 AcT Diff 2	21	81.758	0.815	1.00	61.300	102.200				
2021524z	9 3D	3 Neutrophil	4 JT - Coult	14	82.221	0.763	0.93	61.700	102.800				
2021525z	8 3ST	1 Lymphocyte	1 KX 21 - Sy	40	11.768	0.824	7.00	8.800	14.700				
2021525z	8 3ST	1 Lymphocyte	3 ABBOTT C-D	44	14.484	1.619	11.18	10.900	18.100				
2021525z	8 3ST	2 Mix M/E/Ba	1 KX 21 - Sy	42	18.788	1.084	5.77	14.100	23.500				
2021525z	8 3ST	2 Mix M/E/Ba	3 ABBOTT C-D	47	13.187	2.320	17.59	9.900	16.500				
2021525z	8 3ST	3 Neutrophil	1 KX 21 - Sy	40	69.524	1.043	1.50	52.100	86.900				
2021525z	8 3ST	3 Neutrophil	3 ABBOTT C-D	44	72.793	1.866	2.56	54.600	91.000				
2021525z	9 3D	1 Lymphocyte	2 AcT Diff 2	23	61.629	7.343	11.91	46.200	77.000				
2021525z	9 3D	1 Lymphocyte	4 JT - Coult	15	62.807	2.580	4.11	47.100	78.500				
2021525z	9 3D	2 Mix M/E/Ba	2 AcT Diff 2	22	5.520	1.320	23.91	3.500	7.500				

## Participant Summary

### MONTH 6 OF YEAR 2021

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 128 DIFF 3 PARAMETER INS

ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2021525z	9	3D	2	Mix M/E/Ba	4	JT - Coult	14	4.493	1.594	35.48	2.500	6.500
2021525z	9	3D	3	Neutrophil	2	AcT Diff 2	20	31.374	1.421	4.53	23.500	39.200
2021525z	9	3D	3	Neutrophil	4	JT - Coult	14	32.243	1.863	5.78	24.200	40.300

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
549 RED CELL COUNT (RBC)			CLIA TEST ID #: 775		EVALUATION CRITERIA: TARGET VALUE 6 %							
2021-521	2	ACT PENTRA	125	COULTER AC			138	5.222	0.085	1.62	4.910	5.540
2021-521	2	ACT PENTRA	130	ABX PENTRA			25	5.176	0.083	1.61	4.870	5.490
2021-521	3	ADVIA 120	116	ADVIA-120			16	5.254	0.076	1.45	4.940	5.570
2021-521	7	DXH500 Ser	149	BC DXH 500			26	5.170	0.095	1.85	4.860	5.480
2021-521	8	3 ST	84	ABBOTT C-D			46	5.668	0.134	2.36	5.330	6.010
2021-521	8	3 ST	98	SYSMEX K-			17	5.619	0.078	1.38	5.280	5.960
2021-521	8	3 ST	138	SY KX-21N			26	5.594	0.064	1.14	5.260	5.930
2021-521	9	3 D	33	COULTER JT			15	5.641	0.076	1.35	5.300	5.980
2021-521	9	3 D	120	COULTER			22	5.582	0.147	2.63	5.250	5.920
2021-522	2	ACT PENTRA	125	COULTER AC			138	4.627	0.072	1.55	4.350	4.900
2021-522	2	ACT PENTRA	130	ABX PENTRA			25	4.566	0.090	1.96	4.290	4.840
2021-522	3	ADVIA 120	116	ADVIA-120			16	4.470	0.094	2.10	4.200	4.740
2021-522	7	DXH500 Ser	149	BC DXH 500			26	2.525	0.054	2.14	2.370	2.680
2021-522	8	3 ST	84	ABBOTT C-D			46	4.074	0.072	1.78	3.830	4.320
2021-522	8	3 ST	98	SYSMEX K-			17	3.956	0.056	1.41	3.720	4.190
2021-522	8	3 ST	138	SY KX-21N			26	3.968	0.063	1.58	3.730	4.210
2021-522	9	3 D	33	COULTER JT			15	4.592	0.081	1.77	4.320	4.870
2021-522	9	3 D	120	COULTER			22	4.565	0.102	2.24	4.290	4.840

## Participant Summary

MONTH 6 OF YEAR 2021

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
549	RED CELL COUNT (RBC)	CLIA TEST ID #: 775	EVALUATION CRITERIA: TARGET VALUE 6 %						
2021-523	2 ACT PENTRA	125 COULTER AC		138	2.171	0.045	2.08	2.040	2.300
2021-523	2 ACT PENTRA	130 ABX PENTRA		25	2.170	0.032	1.47	2.040	2.300
2021-523	3 ADVIA 120	116 ADVIA-120		16	2.244	0.047	2.08	2.110	2.380
2021-523	7 DXH500 Ser	149 BC DXH 500		26	5.180	0.108	2.09	4.870	5.490
2021-523	8 3 ST	84 ABBOTT C-D		46	2.301	0.062	2.68	2.160	2.440
2021-523	8 3 ST	98 SYSMEX K-		17	2.251	0.039	1.74	2.120	2.390
2021-523	8 3 ST	138 SY KX-21N		26	2.243	0.031	1.37	2.110	2.380
2021-523	9 3 D	33 COULTER JT		15	2.280	0.025	1.10	2.140	2.420
2021-523	9 3 D	120 COULTER		22	2.327	0.064	2.74	2.190	2.470
2021-524	2 ACT PENTRA	125 COULTER AC		138	5.215	0.085	1.62	4.900	5.530
2021-524	2 ACT PENTRA	130 ABX PENTRA		25	5.155	0.077	1.49	4.850	5.460
2021-524	3 ADVIA 120	116 ADVIA-120		16	5.199	0.097	1.87	4.890	5.510
2021-524	7 DXH500 Ser	149 BC DXH 500		26	4.798	0.073	1.51	4.510	5.090
2021-524	8 3 ST	84 ABBOTT C-D		46	5.675	0.112	1.97	5.330	6.020
2021-524	8 3 ST	98 SYSMEX K-		17	5.610	0.057	1.02	5.270	5.950
2021-524	8 3 ST	138 SY KX-21N		26	5.603	0.047	0.84	5.270	5.940
2021-524	9 3 D	33 COULTER JT		15	5.649	0.150	2.66	5.310	5.990
2021-524	9 3 D	120 COULTER		22	5.629	0.093	1.66	5.290	5.970
2021-525	2 ACT PENTRA	125 COULTER AC		138	2.176	0.047	2.14	2.050	2.310
2021-525	2 ACT PENTRA	130 ABX PENTRA		25	2.173	0.044	2.02	2.040	2.300
2021-525	3 ADVIA 120	116 ADVIA-120		16	2.257	0.042	1.87	2.120	2.390
2021-525	7 DXH500 Ser	149 BC DXH 500		26	2.530	0.052	2.05	2.380	2.680
2021-525	8 3 ST	84 ABBOTT C-D		46	2.306	0.065	2.83	2.170	2.440
2021-525	8 3 ST	98 SYSMEX K-		17	2.239	0.032	1.44	2.100	2.370
2021-525	8 3 ST	138 SY KX-21N		26	2.247	0.028	1.26	2.110	2.380
2021-525	9 3 D	33 COULTER JT		15	2.292	0.062	2.72	2.150	2.430
2021-525	9 3 D	120 COULTER		22	2.328	0.069	2.99	2.190	2.470



## Participant Summary

### MONTH 6 OF YEAR 2021

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
550	HEMATOCRIT (HCT)			CLIA TEST ID #: 785							
				EVALUATION CRITERIA: TARGET VALUE 6 %							
2021-521	2 ACT PENTRA	125 COULTER AC			138	45.530	0.797	1.75	42.800	48.300	
2021-521	2 ACT PENTRA	130 ABX PENTRA			25	45.388	0.785	1.73	42.700	48.100	
2021-521	3 ADVIA 120	116 ADVIA-120			16	46.650	1.307	2.80	43.900	49.400	
2021-521	7 DXH500 Ser	149 BC DXH 500			25	49.104	1.118	2.28	46.200	52.100	
2021-521	8 3 ST	84 ABBOTT C-D			46	53.120	1.636	3.08	49.900	56.300	
2021-521	8 3 ST	98 SYSMEX K-			17	49.276	0.798	1.62	46.300	52.200	
2021-521	8 3 ST	138 SY KX-21N			26	48.832	0.818	1.68	45.900	51.800	
2021-521	9 3 D	33 COULTER JT			15	51.880	1.119	2.16	48.800	55.000	
2021-521	9 3 D	120 COULTER			22	51.745	1.464	2.83	48.600	54.800	
2021-522	2 ACT PENTRA	125 COULTER AC			138	37.404	0.758	2.03	35.200	39.600	
2021-522	2 ACT PENTRA	130 ABX PENTRA			25	37.092	0.643	1.73	34.900	39.300	
2021-522	3 ADVIA 120	116 ADVIA-120			16	36.119	1.133	3.14	34.000	38.300	
2021-522	7 DXH500 Ser	149 BC DXH 500			25	19.720	0.364	1.85	18.500	20.900	
2021-522	8 3 ST	84 ABBOTT C-D			46	35.443	1.068	3.01	33.300	37.600	
2021-522	8 3 ST	98 SYSMEX K-			17	31.871	0.653	2.05	30.000	33.800	
2021-522	8 3 ST	138 SY KX-21N			26	32.027	0.820	2.56	30.100	33.900	
2021-522	9 3 D	33 COULTER JT			15	38.720	0.898	2.32	36.400	41.000	
2021-522	9 3 D	120 COULTER			22	38.568	0.615	1.59	36.300	40.900	
2021-523	2 ACT PENTRA	125 COULTER AC			138	16.040	0.383	2.39	15.100	17.000	
2021-523	2 ACT PENTRA	130 ABX PENTRA			25	15.913	0.391	2.46	15.000	16.900	
2021-523	3 ADVIA 120	116 ADVIA-120			16	15.681	0.419	2.67	14.700	16.600	
2021-523	7 DXH500 Ser	149 BC DXH 500			25	49.304	1.126	2.28	46.300	52.300	
2021-523	8 3 ST	84 ABBOTT C-D			46	18.033	0.540	2.99	17.000	19.100	
2021-523	8 3 ST	98 SYSMEX K-			17	16.700	0.484	2.90	15.700	17.700	
2021-523	8 3 ST	138 SY KX-21N			26	16.608	0.288	1.74	15.600	17.600	
2021-523	9 3 D	33 COULTER JT			15	16.957	0.180	1.06	15.900	18.000	
2021-523	9 3 D	120 COULTER			22	17.345	0.447	2.57	16.300	18.400	

## Participant Summary

MONTH 6 OF YEAR 2021

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
550	HEMATOCRIT (HCT)	CLIA TEST ID #: 785	EVALUATION CRITERIA: TARGET VALUE	6 %					
2021-524	2 ACT PENTRA	125 COULTER AC		138	45.463	0.819	1.80	42.700	48.200
2021-524	2 ACT PENTRA	130 ABX PENTRA		25	45.128	0.849	1.88	42.400	47.800
2021-524	3 ADVIA 120	116 ADVIA-120		16	46.156	1.559	3.38	43.400	48.900
2021-524	7 DXH500 Ser	149 BC DXH 500		25	43.576	0.924	2.12	41.000	46.200
2021-524	8 3 ST	84 ABBOTT C-D		46	53.129	1.476	2.78	49.900	56.300
2021-524	8 3 ST	98 SYSMEX K-		17	49.018	0.915	1.87	46.100	52.000
2021-524	8 3 ST	138 SY KX-21N		26	49.028	0.990	2.02	46.100	52.000
2021-524	9 3 D	33 COULTER JT		15	52.120	1.818	3.49	49.000	55.200
2021-524	9 3 D	120 COULTER		22	52.320	1.169	2.24	49.200	55.500
2021-525	2 ACT PENTRA	125 COULTER AC		138	16.062	0.377	2.35	15.100	17.000
2021-525	2 ACT PENTRA	130 ABX PENTRA		25	15.842	0.351	2.22	14.900	16.800
2021-525	3 ADVIA 120	116 ADVIA-120		16	15.744	0.377	2.40	14.800	16.700
2021-525	7 DXH500 Ser	149 BC DXH 500		25	19.752	0.344	1.74	18.600	20.900
2021-525	8 3 ST	84 ABBOTT C-D		46	18.109	0.631	3.49	17.000	19.200
2021-525	8 3 ST	98 SYSMEX K-		17	16.525	0.185	1.12	15.500	17.500
2021-525	8 3 ST	138 SY KX-21N		26	16.672	0.238	1.42	15.700	17.700
2021-525	9 3 D	33 COULTER JT		15	17.087	0.453	2.65	16.100	18.100
2021-525	9 3 D	120 COULTER		22	17.435	0.543	3.12	16.400	18.500
551	HEMOGLOBIN (HGB)	CLIA TEST ID #: 795	EVALUATION CRITERIA: TARGET VALUE	7 % OR 2.00 {LOWER}					
2021-521	2 ACT PENTRA	125 COULTER AC		138	16.406	0.244	1.49	15.300	17.600
2021-521	2 ACT PENTRA	130 ABX PENTRA		25	16.592	0.198	1.19	15.400	17.800
2021-521	3 ADVIA 120	116 ADVIA-120		16	17.194	0.244	1.42	16.000	18.400
2021-521	7 DXH500 Ser	149 BC DXH 500		26	17.388	0.353	2.03	16.200	18.600
2021-521	8 3 ST	84 ABBOTT C-D		46	18.213	0.484	2.66	16.900	19.500
2021-521	8 3 ST	98 SYSMEX K-		17	18.288	0.351	1.92	17.000	19.600
2021-521	8 3 ST	138 SY KX-21N		26	18.058	0.220	1.22	16.800	19.300
2021-521	9 3 D	33 COULTER JT		15	18.653	0.400	2.14	17.300	20.000
2021-521	9 3 D	120 COULTER		22	18.270	0.514	2.81	17.000	19.500

## Participant Summary

MONTH 6 OF YEAR 2021

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS			LABS	VALUE	DEVIATION	CV	LOW	HIGH
551	HEMOGLOBIN (HGB)	CLIA TEST ID #: 795	EVALUATION CRITERIA: TARGET VALUE	7	%	OR	2.00	{LOWER}			
2021-522	2	ACT PENTRA	125 COULTER AC			138	13.471	0.194	1.44	12.500	14.400
2021-522	2	ACT PENTRA	130 ABX PENTRA			25	13.471	0.149	1.10	12.500	14.400
2021-522	3	ADVIA 120	116 ADVIA-120			16	13.363	0.180	1.35	12.400	14.300
2021-522	7	DXH500 Ser	149 BC DXH 500			26	6.696	0.087	1.30	6.200	7.200
2021-522	8	3 ST	84 ABBOTT C-D			46	12.209	0.266	2.18	11.400	13.100
2021-522	8	3 ST	98 SYSMEX K-			17	12.059	0.200	1.66	11.200	12.900
2021-522	8	3 ST	138 SY KX-21N			26	11.973	0.174	1.46	11.100	12.800
2021-522	9	3 D	33 COULTER JT			15	13.633	0.199	1.46	12.700	14.600
2021-522	9	3 D	120 COULTER			22	13.550	0.399	2.95	12.600	14.500
2021-523	2	ACT PENTRA	125 COULTER AC			138	5.685	0.111	1.96	5.300	6.100
2021-523	2	ACT PENTRA	130 ABX PENTRA			25	5.550	0.065	1.16	5.200	5.900
2021-523	3	ADVIA 120	116 ADVIA-120			16	5.806	0.090	1.55	5.400	6.200
2021-523	7	DXH500 Ser	149 BC DXH 500			26	17.362	0.324	1.86	16.100	18.600
2021-523	8	3 ST	84 ABBOTT C-D			46	6.426	0.151	2.35	6.000	6.900
2021-523	8	3 ST	98 SYSMEX K-			17	6.300	0.164	2.61	5.900	6.700
2021-523	8	3 ST	138 SY KX-21N			26	6.192	0.120	1.93	5.800	6.600
2021-523	9	3 D	33 COULTER JT			15	5.760	0.196	3.40	5.400	6.200
2021-523	9	3 D	120 COULTER			22	6.026	0.180	2.99	5.600	6.400
2021-524	2	ACT PENTRA	125 COULTER AC			138	16.431	0.265	1.61	15.300	17.600
2021-524	2	ACT PENTRA	130 ABX PENTRA			25	16.550	0.163	0.99	15.400	17.700
2021-524	3	ADVIA 120	116 ADVIA-120			16	17.131	0.153	0.89	15.900	18.300
2021-524	7	DXH500 Ser	149 BC DXH 500			26	15.152	0.206	1.36	14.100	16.200
2021-524	8	3 ST	84 ABBOTT C-D			46	18.261	0.412	2.26	17.000	19.500
2021-524	8	3 ST	98 SYSMEX K-			17	18.182	0.281	1.55	16.900	19.500
2021-524	8	3 ST	138 SY KX-21N			26	18.046	0.227	1.26	16.800	19.300
2021-524	9	3 D	33 COULTER JT			15	18.620	0.323	1.73	17.300	19.900
2021-524	9	3 D	120 COULTER			22	18.410	0.485	2.63	17.100	19.700

## Participant Summary

MONTH 6 OF YEAR 2021

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
551	HEMOGLOBIN (HGB)	CLIA TEST ID #: 795	EVALUATION CRITERIA: TARGET VALUE	7	% OR 2.00	{LOWER}				
2021-525	2 ACT PENTRA	125 COULTER AC		138	5.681	0.111	1.95	5.300	6.100	
2021-525	2 ACT PENTRA	130 ABX PENTRA		25	5.550	0.065	1.16	5.200	5.900	
2021-525	3 ADVIA 120	116 ADVIA-120		16	5.831	0.098	1.68	5.400	6.200	
2021-525	7 DXH500 Ser	149 BC DXH 500		26	6.723	0.115	1.72	6.300	7.200	
2021-525	8 3 ST	84 ABBOTT C-D		46	6.460	0.139	2.15	6.000	6.900	
2021-525	8 3 ST	98 SYSMEX K-		17	6.294	0.143	2.28	5.900	6.700	
2021-525	8 3 ST	138 SY KX-21N		26	6.227	0.126	2.02	5.800	6.700	
2021-525	9 3 D	33 COULTER JT		15	5.767	0.170	2.95	5.400	6.200	
2021-525	9 3 D	120 COULTER		22	6.050	0.206	3.41	5.600	6.500	
552	WHITE CELL COUNT(WBC)	CLIA TEST ID #: 805	EVALUATION CRITERIA: TARGET VALUE	15	%					
2021-521	2 ACT PENTRA	125 COULTER AC		138	18.033	0.549	3.05	15.300	20.700	
2021-521	2 ACT PENTRA	130 ABX PENTRA		25	17.804	0.562	3.16	15.100	20.500	
2021-521	3 ADVIA 120	116 ADVIA-120		16	17.875	0.774	4.33	15.200	20.600	
2021-521	7 DXH500 Ser	149 BC DXH 500		26	19.396	0.456	2.35	16.500	22.300	
2021-521	8 3 ST	84 ABBOTT C-D		46	21.898	0.842	3.85	18.600	25.200	
2021-521	8 3 ST	98 SYSMEX K-		17	20.088	0.389	1.94	17.100	23.100	
2021-521	8 3 ST	138 SY KX-21N		26	20.100	0.332	1.65	17.100	23.100	
2021-521	9 3 D	33 COULTER JT		15	21.607	0.514	2.38	18.400	24.800	
2021-521	9 3 D	120 COULTER		22	20.985	0.589	2.81	17.800	24.100	
2021-522	2 ACT PENTRA	125 COULTER AC		138	7.552	0.260	3.44	6.400	8.700	
2021-522	2 ACT PENTRA	130 ABX PENTRA		25	7.512	0.221	2.95	6.400	8.600	
2021-522	3 ADVIA 120	116 ADVIA-120		16	7.550	0.364	4.82	6.400	8.700	
2021-522	7 DXH500 Ser	149 BC DXH 500		26	2.004	0.119	5.95	1.700	2.300	
2021-522	8 3 ST	84 ABBOTT C-D		46	8.784	0.436	4.96	7.500	10.100	
2021-522	8 3 ST	98 SYSMEX K-		17	7.918	0.134	1.69	6.700	9.100	
2021-522	8 3 ST	138 SY KX-21N		26	7.931	0.190	2.39	6.700	9.100	
2021-522	9 3 D	33 COULTER JT		15	7.993	0.184	2.31	6.800	9.200	
2021-522	9 3 D	120 COULTER		22	8.150	0.260	3.19	6.900	9.400	

## Participant Summary

MONTH 6 OF YEAR 2021

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
552	WHITE CELL COUNT(WBC	CLIA TEST ID #: 805	EVALUATION CRITERIA: TARGET VALUE	15	%				
2021-523	2 ACT PENTRA	125 COULTER AC		138	2.776	0.107	3.86	2.400	3.200
2021-523	2 ACT PENTRA	130 ABX PENTRA		25	2.732	0.088	3.23	2.300	3.100
2021-523	3 ADVIA 120	116 ADVIA-120		16	2.925	0.075	2.56	2.500	3.400
2021-523	7 DXH500 Ser	149 BC DXH 500		26	19.420	0.441	2.27	16.500	22.300
2021-523	8 3 ST	84 ABBOTT C-D		46	3.091	0.190	6.13	2.600	3.600
2021-523	8 3 ST	98 SYSMEX K-		17	2.669	0.068	2.55	2.300	3.100
2021-523	8 3 ST	138 SY KX-21N		26	2.684	0.105	3.90	2.300	3.100
2021-523	9 3 D	33 COULTER JT		15	2.013	0.102	5.09	1.700	2.300
2021-523	9 3 D	120 COULTER		22	2.200	0.077	3.52	1.900	2.500
2021-524	2 ACT PENTRA	125 COULTER AC		138	17.980	0.538	2.99	15.300	20.700
2021-524	2 ACT PENTRA	130 ABX PENTRA		25	17.840	0.539	3.02	15.200	20.500
2021-524	3 ADVIA 120	116 ADVIA-120		16	17.856	0.889	4.98	15.200	20.500
2021-524	7 DXH500 Ser	149 BC DXH 500		26	7.396	0.224	3.02	6.300	8.500
2021-524	8 3 ST	84 ABBOTT C-D		46	21.938	1.029	4.69	18.600	25.200
2021-524	8 3 ST	98 SYSMEX K-		17	20.053	0.415	2.07	17.000	23.100
2021-524	8 3 ST	138 SY KX-21N		26	20.054	0.539	2.69	17.000	23.100
2021-524	9 3 D	33 COULTER JT		15	21.533	0.382	1.78	18.300	24.800
2021-524	9 3 D	120 COULTER		22	21.075	0.593	2.81	17.900	24.200
2021-525	2 ACT PENTRA	125 COULTER AC		138	2.774	0.123	4.42	2.400	3.200
2021-525	2 ACT PENTRA	130 ABX PENTRA		25	2.752	0.106	3.86	2.300	3.200
2021-525	3 ADVIA 120	116 ADVIA-120		16	2.963	0.086	2.89	2.500	3.400
2021-525	7 DXH500 Ser	149 BC DXH 500		26	1.992	0.107	5.38	1.700	2.300
2021-525	8 3 ST	84 ABBOTT C-D		46	3.111	0.198	6.36	2.600	3.600
2021-525	8 3 ST	98 SYSMEX K-		17	2.724	0.100	3.68	2.300	3.100
2021-525	8 3 ST	138 SY KX-21N		26	2.719	0.100	3.68	2.300	3.100
2021-525	9 3 D	33 COULTER JT		15	2.080	0.083	4.00	1.800	2.400
2021-525	9 3 D	120 COULTER		22	2.245	0.086	3.85	1.900	2.600

## Participant Summary

MONTH 6 OF YEAR 2021

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 134 PLATELET COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
553	PLATELET COUNT	CLIA TEST ID #: 815	EVALUATION CRITERIA: TARGET VALUE 25 %								
2021-521	2 ACT5 PENTR	73 COULTER AC		135	480.530	19.664	4.09	360.000	601.000		
2021-521	2 ACT5 PENTR	78 ABX PENTRA		25	481.292	12.388	2.57	361.000	602.000		
2021-521	3 ADVIA 120	64 ADVIA-120		16	432.375	27.377	6.33	324.000	540.000		
2021-521	8 3 ST	31 ABBOTT C-D		46	377.804	26.438	7.00	283.000	472.000		
2021-521	8 3 ST	39 SYSMEX K-		16	394.563	15.676	3.97	296.000	493.000		
2021-521	8 3 ST	84 KX21,300		27	388.074	24.894	6.41	291.000	485.000		
2021-521	9 3 D	50 COULT.JT,M		14	557.929	25.095	4.50	418.000	697.000		
2021-521	9 3 D	68 COULTERAcT		22	546.600	23.234	4.25	410.000	683.000		
2021-521	10 DxH	94 BC DXH 500		26	507.120	21.765	4.29	380.000	634.000		
2021-522	2 ACT5 PENTR	73 COULTER AC		135	241.045	10.245	4.25	181.000	301.000		
2021-522	2 ACT5 PENTR	78 ABX PENTRA		25	243.280	10.953	4.50	182.000	304.000		
2021-522	3 ADVIA 120	64 ADVIA-120		16	216.938	13.231	6.10	163.000	271.000		
2021-522	8 3 ST	31 ABBOTT C-D		46	195.348	15.868	8.12	147.000	244.000		
2021-522	8 3 ST	39 SYSMEX K-		16	199.063	7.224	3.63	149.000	249.000		
2021-522	8 3 ST	84 KX21,300		27	199.269	10.166	5.10	149.000	249.000		
2021-522	9 3 D	50 COULT.JT,M		14	269.929	9.558	3.54	202.000	337.000		
2021-522	9 3 D	68 COULTERAcT		22	270.190	20.784	7.69	203.000	338.000		
2021-522	10 DxH	94 BC DXH 500		26	78.640	4.489	5.71	59.000	98.000		
2021-523	2 ACT5 PENTR	73 COULTER AC		135	65.903	4.470	6.78	49.000	82.000		
2021-523	2 ACT5 PENTR	78 ABX PENTRA		25	68.440	4.109	6.00	51.000	86.000		
2021-523	3 ADVIA 120	64 ADVIA-120		16	51.688	5.347	10.34	39.000	65.000		
2021-523	8 3 ST	31 ABBOTT C-D		46	66.652	6.162	9.24	50.000	83.000		
2021-523	8 3 ST	39 SYSMEX K-		16	64.000	5.489	8.58	48.000	80.000		
2021-523	8 3 ST	84 KX21,300		27	66.192	5.421	8.19	50.000	83.000		
2021-523	9 3 D	50 COULT.JT,M		14	69.786	3.488	5.00	52.000	87.000		
2021-523	9 3 D	68 COULTERAcT		22	72.048	6.447	8.95	54.000	90.000		

**Participant Summary**

**MONTH 6 OF YEAR 2021**

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 134 PLATELET COUNT NEW							
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE		
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2021-523	10 DxH	94 BC DXH 500		26	506.320	23.201	4.58	380.000	633.000		
553 PLATELET COUNT				CLIA TEST ID #: 815 EVALUATION CRITERIA: TARGET VALUE 25 %							
2021-524	2 ACT5 PENTR	73 COULTER AC		135	477.410	19.620	4.11	358.000	597.000		
2021-524	2 ACT5 PENTR	78 ABX PENTRA		25	479.583	13.835	2.88	360.000	599.000		
2021-524	3 ADVIA 120	64 ADVIA-120		16	429.625	31.444	7.32	322.000	537.000		
2021-524	8 3 ST	31 ABBOTT C-D		46	377.783	29.832	7.90	283.000	472.000		
2021-524	8 3 ST	39 SYSMEX K-		16	394.467	13.851	3.51	296.000	493.000		
2021-524	8 3 ST	84 KX21,300		27	388.222	28.690	7.39	291.000	485.000		
2021-524	9 3 D	50 COULT.JT,M		14	553.357	22.057	3.99	415.000	692.000		
2021-524	9 3 D	68 COULTERAcT		22	559.650	19.772	3.53	420.000	700.000		
2021-524	10 DxH	94 BC DXH 500		26	265.080	11.737	4.43	199.000	331.000		
2021-525	2 ACT5 PENTR	73 COULTER AC		135	66.429	5.028	7.57	50.000	83.000		
2021-525	2 ACT5 PENTR	78 ABX PENTRA		25	68.320	4.315	6.32	51.000	85.000		
2021-525	3 ADVIA 120	64 ADVIA-120		16	53.313	5.542	10.40	40.000	67.000		
2021-525	8 3 ST	31 ABBOTT C-D		46	66.761	6.294	9.43	50.000	83.000		
2021-525	8 3 ST	39 SYSMEX K-		16	67.000	5.136	7.67	50.000	84.000		
2021-525	8 3 ST	84 KX21,300		27	65.538	3.723	5.68	49.000	82.000		
2021-525	9 3 D	50 COULT.JT,M		14	70.000	2.591	3.70	53.000	88.000		
2021-525	9 3 D	68 COULTERAcT		22	70.429	4.614	6.55	53.000	88.000		
2021-525	10 DxH	94 BC DXH 500		26	75.480	6.481	8.59	57.000	94.000		

SPEC: 20 HEMATOLOGY		SUB: 75 BODY FLUID		GRP: 145 BODY FLUID CELL COU.							
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE		
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
159 BF RED CELL COUNT				CLIA TEST ID #: 0 EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {GREATER}							
2021-561				48	0.000	0.000	0.00	0.000	0.000		

**Participant Summary**

**MONTH 6 OF YEAR 2021**

SPEC: 20 HEMATOLOGY                      SUB: 75 BODY FLUID                      GRP: 145 BODY FLUID CELL COU.

ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
159	BF RED CELL COUNT	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3			SD OR 25 %	{GREATER}		
	2021-562				48	0.000	0.000	0.00	0.000	0.000
	2021-563				48	0.000	0.000	0.00	0.000	0.000
	2021-564				48	0.000	0.000	0.00	0.000	0.000
	2021-565				48	0.000	0.000	0.00	0.000	0.000



## Participant Summary

### MONTH 6 OF YEAR 2021

SPE: 30 IMMUNOHEMATOLOGY		SUB: 80 ABO-RH				GRP: 150 ABO-RH							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
083 ABO GROUP													
2021-571				001 003	001 003		001 - A	89	87	89	100		
2021-571				001 003	001 003		002 - A1	89	2	89	100		
2021-572				008 008	008 008		008 - O	89	89	89	100		
2021-573				004 004	004 004		004 - B	89	89	89	100		
2021-574				008 008	008 008		008 - O	89	89	89	100		
2021-575				001 003	001 003		001 - A	89	86	89	100		
2021-575				001 003	001 003		002 - A1	89	3	89	100		
126 RH TYPE													
2021-571				001 003	001 003		001 - Rh+	89	89	89	100		
2021-572				003 004	003 004		003 - Rh-Du np	89	12	89	100		
2021-572				003 004	003 004		004 - Rh-	89	77	89	100		
2021-573				001 003	001 003		001 - Rh+	89	89	89	100		
2021-574				001 003	001 003		001 - Rh+	89	89	89	100		
2021-575				003 004	003 004		003 - Rh-Du np	89	12	89	100		
2021-575				003 004	003 004		004 - Rh-	89	77	89	100		

### Participant Summary

MONTH 6 OF YEAR 2021

SPE: 30 IMMUNOHEMATOLOGY				SUB: 90 COOMBS				GRP: 160 Indirect COOMBS			
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
084 INDIRECT COOMBS											
2021-581				001 001	001 001		001 - NEGATIVE	68	68	68	100
2021-582				002 002	002 002		002 - POSITIVE	68	68	68	100
2021-583				001 001	001 001		001 - NEGATIVE	68	68	68	100
2021-584				002 002	002 002		002 - POSITIVE	68	68	68	100
2021-585				001 001	001 001		001 - NEGATIVE	68	68	68	100
SPE: 30 IMMUNOHEMATOLOGY				SUB: 90 COOMBS				GRP: 165 Direct COOMBS			
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
179 DIRECT ANTIG(COOMBS)											
2021-291	001 Poly AHG	001 Gel		002 004			003 - 3+	13	2	13	100
2021-291	001 Poly AHG	001 Gel		002 004			004 - 4+	13	11	13	100
2021-291	001 Poly AHG	002 Tubo				002 004	002 - 2+	33	26	33	100
2021-291	001 Poly AHG	002 Tubo				002 004	003 - 3+	33	5	33	100
2021-291	001 Poly AHG	002 Tubo				002 004	004 - 4+	33	2	33	100
2021-291	002 MnoAnt-IgG	002 Tubo				002 004	002 - 2+	17	12	17	100
2021-291	002 MnoAnt-IgG	002 Tubo				002 004	003 - 3+	17	4	17	100
2021-291	002 MnoAnt-IgG	002 Tubo				002 004	004 - 4+	17	1	17	100
2021-292	001 Poly AHG	001 Gel		001 001	001 001		001 - Negativo	13	13	13	100
2021-292	001 Poly AHG	002 Tubo		001 001	001 001		001 - Negativo	33	33	33	100

## Participant Summary

### MONTH 6 OF YEAR 2021

SPE: 30 IMMUNOHEMATOLOGY				SUB: 90 COOMBS				GRP: 165 Direct COOMBS									
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH		COMMER LOW/HIGH		REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2021-292	002	MnoAnt-IgG	001	Gel			001	001	001	001			001 - Negativo	10	10	10	100
2021-292	002	MnoAnt-IgG	002	Tubo			001	001	001	001			001 - Negativo	17	17	17	100
179 DIRECT ANTIG(COOMBS)																	
2021-293	001	Poly AHG	001	Gel			001	001	001	001			001 - Negativo	13	13	13	100
2021-293	001	Poly AHG	002	Tubo			001	001	001	001			001 - Negativo	33	33	33	100
2021-293	002	MnoAnt-IgG	001	Gel			001	001	001	001			001 - Negativo	10	10	10	100
2021-293	002	MnoAnt-IgG	002	Tubo			001	001	001	001			001 - Negativo	17	17	17	100
2021-294	001	Poly AHG	001	Gel			001	001	001	001			001 - Negativo	13	13	13	100
2021-294	001	Poly AHG	002	Tubo			001	001	001	001			001 - Negativo	33	33	33	100
2021-294	002	MnoAnt-IgG	001	Gel			001	001	001	001			001 - Negativo	10	10	10	100
2021-294	002	MnoAnt-IgG	002	Tubo			001	001	001	001			001 - Negativo	17	17	17	100
2021-295	001	Poly AHG	001	Gel					002	004			003 - 3+	13	3	13	100
2021-295	001	Poly AHG	001	Gel					002	004			004 - 4+	13	10	13	100
2021-295	001	Poly AHG	002	Tubo			002	004	002	004			002 - 2+	33	28	33	100
2021-295	001	Poly AHG	002	Tubo			002	004	002	004			003 - 3+	33	4	33	100
2021-295	001	Poly AHG	002	Tubo			002	004	002	004			004 - 4+	33	1	33	100
2021-295	002	MnoAnt-IgG	002	Tubo			002	004	002	004			002 - 2+	17	14	17	100
2021-295	002	MnoAnt-IgG	002	Tubo			002	004	002	004			003 - 3+	17	3	17	100

**Participant Summary**

**MONTH 6 OF YEAR 2021**

SPE: 30 IMMUNOHEMATOLOGY												SUB: 100 COMPATIBILITY TESTING												GRP: 170 COMPATIBILITY TEST.											
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH		COMMER LOW/HIGH		REPORTED VALUE		PART LABS		# LABS ANSW		# "SF" LABS		Score														
085 COMPATIBIL. TESTING																																			
2021-591							001	001	001	001			001 - COMPATIBLE		41		41		41		100														
2021-592							002	002	002	002			002 - INCOMPATIB		41		41		41		100														
2021-593							001	001	001	001			001 - COMPATIBLE		41		41		41		100														
2021-594							002	002	002	002			002 - INCOMPATIB		41		41		41		100														
2021-595							001	001	001	001			001 - COMPATIBLE		41		41		41		100														

## Participant Summary

MONTH 6 OF YEAR 2021

SPE: 40 IMMUNOLOGY			SUB: 120 GENERAL				GRP: 230 HBsAG, ANTI HBC, HIV					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
093 ANTI-HUMAN IMM. (HIV)												
2021-601	055	ALERE DETE		001 001	001 001		001 - NEG/NR	29	29	29	100	
2021-602	055	ALERE DETE		001 001	001 001		001 - NEG/NR	29	29	29	100	
2021-603	055	ALERE DETE		002 002	002 002		002 - POS/R	29	29	29	100	
2021-604	055	ALERE DETE		002 002	002 002		002 - POS/R	29	29	29	100	
2021-605	055	ALERE DETE		002 002	002 002		002 - POS/R	29	29	29	100	